SchizophreniaNCT07618767
A Computational Neuroscience Perspective on the Shared Social Cognitive Deficits of Autism and Schizophrenia
An observational study of Schizophrenia and Autism Spectrum Disorder, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
This retrospective cohort study will examine shared neural mechanisms of social cognitive deficits in adults with autism spectrum disorder and adults with schizophrenia using existing clinical, behavioral, and neuroimaging data from National Taiwan University Hospital cohort studies. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Schizophrenia, Autism Spectrum Disorder
- How many people
- 267 participants
- Where
- 1 siteTaiwan
- Study dates
- 30 Sep 2025to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This retrospective cohort study will use pre-existing clinical, behavioral, and neuroimaging data from adult participants who were previously enrolled in cohort studies conducted at National Taiwan University Hospital. The study population includes adults with autism spectrum disorder, adults with schizophrenia, and healthy control participants. Available data include structural MRI, resting-state functional MRI, and symptom or behavioral assessments relevant to social cognition and psychiatric symptoms, including the Social Responsiveness Scale and the Positive and Negative Syndrome Scale when applicable. No new participants will be prospectively recruited, and no intervention will be administered.
Who may be able to join
- Previously enrolled in one of the source cohort studies approved by the institutional review board of National Taiwan University Hospital.
- Adult participants belonging to one of the following groups:
- Autism spectrum disorder group: participants with a clinical diagnosis of autism spectrum disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
- Schizophrenia group: participants with a clinical diagnosis of schizophrenia according to DSM-5 criteria.
- Healthy control group: participants without a history of autism spectrum disorder, schizophrenia, or other major psychiatric or neurodevelopmental disorders according to available source cohort records.
- Availability of resting-state functional MRI data acquired under the study MRI protocol.
- For participants in the autism spectrum disorder group, availability of autistic trait or social functioning measures, such as the Social Responsiveness Scale, when used in symptom-association analyses.
- For participants in the schizophrenia group, availability of psychiatric symptom measures, such as the Positive and Negative Syndrome Scale, when used in symptom-association analyses.
Who cannot join
- Missing or incomplete MRI data.
- Poor-quality MRI data due to severe artifacts, failed preprocessing, failed registration, or incomplete brain coverage.
- Excessive head motion during resting-state fMRI that prevents reliable analysis.
- Missing essential demographic or diagnostic information.
- Missing required clinical or behavioral measures for specific association analyses.
- Healthy controls with documented major psychiatric or neurodevelopmental disorders, if identified in source cohort records.
Trial locations and contacts
1 site in 1 country.
About this study
This retrospective cohort study will examine shared neural mechanisms of social cognitive deficits in adults with autism spectrum disorder and adults with schizophrenia using existing clinical, behavioral, and neuroimaging data from National Taiwan University Hospital cohort studies. The study will include adults with autism spectrum disorder, adults with schizophrenia, and healthy control participants.
Resting-state functional magnetic resonance imaging (MRI) and structural MRI data will be analyzed to estimate default mode network functional transition indices. These indices will be compared between diagnostic groups and examined in association with social cognitive and psychiatric symptom measures, including the Social Responsiveness Scale (SRS) and the Positive and Negative Syndrome Scale (PANSS) when applicable. No new participants will be recruited, and no intervention will be administered. The study will use previously collected data from 80 adults with autism spectrum disorder, 79 adults with schizophrenia, and 108 healthy controls.
- Conditions
- Schizophrenia, Autism Spectrum Disorder
- Keywords
- schizophrenia, autism spectrum disorder, fMRI, social cognition
- Medical subject headings
- Schizophrenia, Autism Spectrum Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy controls | Not described | |
| Autism Spectrum Disorder | Not described | |
| Schizophrenia | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Default Mode Network mean functional state transition velocity, DMNμV
DMNμV will be derived from resting-state functional MRI data. Multi-voxel activity patterns within the default mode network will be projected into a two-dimensional state space using multidimensional scaling. The Euclidean distance between consecutive functional states will be calculated, and the mean transition velocity across time points will be used as an index of default mode network functional state stability. Lower DMNμV indicates slower state transition and higher functional state stability.
Measured: Baseline / retrospective assessment from pre-existing resting-state fMRI data
Secondary outcomes (3)
Default Mode Network Root Mean Square of Successive Differences
The root mean square of successive differences in the default mode network signal will be calculated from the mean time series of default mode network regions of interest. This measure reflects temporal variation in mean default mode network activity across consecutive resting-state fMRI time points. Lower values indicate smaller temporal variation and greater signal stability.
Measured: Baseline / retrospective assessment from existing resting-state fMRI data
Social Responsiveness Scale Score, SRS
The Social Responsiveness Scale will be used to measure autistic traits and social functioning. The SRS is a 65-item rating scale measuring the severity of social impairment and autism-related traits. Each item is rated on a 4-point scale and scored from 0 to 3, with higher scores indicating greater autistic traits or greater impairment in reciprocal social behavior. The total raw score ranges from 0 to 195. Scores will be examined in association with default mode network functional transition indices, particularly among participants with autism spectrum disorder.
Measured: Baseline / retrospective assessment from existing source cohort records
Positive and Negative Syndrome Scale Score, PANSS
The Positive and Negative Syndrome Scale will be used to assess psychiatric symptom severity in participants with schizophrenia. The PANSS consists of 30 clinician-rated items. Each item is rated on a 7-point scale from 1 to 7, where 1 indicates absent symptoms and 7 indicates extreme symptom severity. The PANSS includes three standard subscales: Positive Scale, Negative Scale, and General Psychopathology Scale. The Positive Scale contains 7 items, the Negative Scale contains 7 items, and the General Psychopathology Scale contains 16 items. The PANSS total score is calculated by summing all 30 items and ranges from 30 to 210. Higher scores indicate greater psychiatric symptom severity. Total and subscale scores may be examined in association with default mode network functional transition indices.
Measured: Baseline / retrospective assessment from existing source cohort records
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jun 2026
- Study start30 Sep 2025
- Primary completion23 Jul 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 267 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07618767
- Sponsor's protocol ID
- 202506020RINA
- Status last verified
- May 2026
- First submitted
- 24 May 2026
- Last updated
- 8 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Computational Neuroscience Perspective on the Shared Social Cognitive Deficits of Autism and Schizophrenia
- ClinicalTrials.gov ID
- NCT07618767
- Acronym / sponsor ID
- 202506020RINA
- Conditions
- Schizophrenia, Autism Spectrum Disorder
- Keywords
- schizophrenia, autism spectrum disorder, fMRI, social cognition
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 267 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 30 Sep 2025 (actual)
- Primary completion
- 23 Jul 2026 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 1 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective cohort study will examine shared neural mechanisms of social cognitive deficits in adults with autism spectrum disorder and adults with schizophrenia using existing clinical, behavioral, and neuroimaging data from National Taiwan University Hospital cohort studies. The study will include adults with autism spectrum disorder, adults with schizophrenia, and healthy control participants.
Resting-state functional magnetic resonance imaging (MRI) and structural MRI data will be analyzed to estimate default mode network functional transition indices. These indices will be compared between diagnostic groups and examined in association with social cognitive and psychiatric symptom measures, including the Social Responsiveness Scale (SRS) and the Positive and Negative Syndrome Scale (PANSS) when applicable. No new participants will be recruited, and no intervention will be administered. The study will use previously collected data from 80 adults with autism spectrum disorder, 79 adults with schizophrenia, and 108 healthy controls.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Healthy controls | – | – |
| Autism Spectrum Disorder | – | – |
| Schizophrenia | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- This retrospective cohort study will use pre-existing clinical, behavioral, and neuroimaging data from adult participants who were previously enrolled in cohort studies conducted at National Taiwan University Hospital. The study population includes adults with autism spectrum disorder, adults with schizophrenia, and healthy control participants. Available data include structural MRI, resting-state functional MRI, and symptom or behavioral assessments relevant to social cognition and psychiatric symptoms, including the Social Responsiveness Scale and the Positive and Negative Syndrome Scale when applicable. No new participants will be prospectively recruited, and no intervention will be administered.
Key inclusion criteria (8 listed)
- Previously enrolled in one of the source cohort studies approved by the institutional review board of National Taiwan University Hospital.
- Adult participants belonging to one of the following groups:
- Availability of resting-state functional MRI data acquired under the study MRI protocol.
- For participants in the autism spectrum disorder group, availability of autistic trait or social functioning measures, such as the Social Responsiveness Scale, when used in symptom-association analyses.
- For participants in the schizophrenia group, availability of psychiatric symptom measures, such as the Positive and Negative Syndrome Scale, when used in symptom-association analyses.
Key exclusion criteria (6 listed)
- Missing or incomplete MRI data.
- Poor-quality MRI data due to severe artifacts, failed preprocessing, failed registration, or incomplete brain coverage.
- Excessive head motion during resting-state fMRI that prevents reliable analysis.
- Missing essential demographic or diagnostic information.
- Missing required clinical or behavioral measures for specific association analyses.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Default Mode Network mean functional state transition velocity, DMNμV
Time frame: Baseline / retrospective assessment from pre-existing resting-state fMRI data
DMNμV will be derived from resting-state functional MRI data. Multi-voxel activity patterns within the default mode network will be projected into a two-dimensional state space using multidimensional scaling. The Euclidean distance between consecutive functional states will be calculated, and the mean transition velocity across time points will be used as an index of default mode network functional state stability. Lower DMNμV indicates slower state transition and higher functional state stability.
3 secondary outcomes
Default Mode Network Root Mean Square of Successive Differences
Time frame: Baseline / retrospective assessment from existing resting-state fMRI data
Social Responsiveness Scale Score, SRS
Time frame: Baseline / retrospective assessment from existing source cohort records
Positive and Negative Syndrome Scale Score, PANSS
Time frame: Baseline / retrospective assessment from existing source cohort records
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Schizophrenia
RecruitingPhase 2
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Schizophrenia
RecruitingPhase 3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Schizophrenia
Recruiting
Magnetic Seizure Therapy for Schizophrenia - Trial
Treatment Resistant Schizophrenia, Schizophrenia
Recruiting
Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention
Schizophrenia Spectrum Disorders (SSD)
RecruitingObservational study
Sensory Profile and Early Clinical Signs of Calm Room Users
Psychotic Disorders, Personality Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Schizophrenia and Autism Spectrum Disorder, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Default Mode Network mean functional state transition velocity, DMNμV (time frame: Baseline / retrospective assessment from pre-existing resting-state fMRI data). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026.